**10. Conclusion**

Colon cancer is one of the leading cause or morbidity and mortality in the world with incidence increasing, especially in younger population. Advances in systemic chemotherapeutic options have improved the survival. Adjuvant chemotherapy has been shown to reduce the risk of recurrence after resection of primary colon cancer; however, it is associated with chemotherapy related morbidity and mortality. Clinicopathological features and molecular characteristics of the tumor need to be carefully assessed and adjuvant therapy should be tailored accordingly in order to avoid futile treatment and serious toxicities. Advances in genomic profiling and evolution of detection of circulating tumor DNA are promising and may guide the choice and intensity of treatment in the future.

**175**

**Author details**

Thiru Prasanna1,2,3\* and Desmond Yip1,2

1 Canberra Hospital, Garran, Australia

3 University of Canberra, Canberra, Australia

provided the original work is properly cited.

\*Address all correspondence to: thiru.prasanna@act.gov.au

2 ANU Medical School, Australian National University, Canberra, Australia

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

*Adjuvant Therapies in Colon Cancer*

*DOI: http://dx.doi.org/10.5772/intechopen.93874*
